Somewhat Positive Media Coverage Somewhat Unlikely to Affect Insys Therapeutics (INSY) Stock Price

Media stories about Insys Therapeutics (NASDAQ:INSY) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Insys Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 44.9684797536813 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the media stories that may have impacted Accern Sentiment’s scoring:

How to Become a New Pot Stock Millionaire

NASDAQ:INSY traded up $0.51 during trading hours on Tuesday, hitting $6.78. 866,903 shares of the company’s stock traded hands, compared to its average volume of 1,261,897. The firm has a market capitalization of $448.49, a price-to-earnings ratio of -13.88 and a beta of 1.13. Insys Therapeutics has a 52 week low of $4.10 and a 52 week high of $15.02.

Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings data on Thursday, March 8th. The specialty pharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.47). The business had revenue of $31.49 million for the quarter, compared to the consensus estimate of $34.00 million. Insys Therapeutics had a negative net margin of 162.07% and a negative return on equity of 24.02%. Insys Therapeutics’s quarterly revenue was down 42.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.03 EPS. equities analysts predict that Insys Therapeutics will post -0.83 earnings per share for the current year.

INSY has been the subject of several recent research reports. Zacks Investment Research cut Insys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 3rd. Cann reiterated an “average” rating on shares of Insys Therapeutics in a research report on Friday, March 2nd. ValuEngine upgraded Insys Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, March 14th. Oppenheimer reiterated a “hold” rating on shares of Insys Therapeutics in a research report on Sunday, March 11th. Finally, Piper Jaffray cut Insys Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Friday, March 9th. Four investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Insys Therapeutics has an average rating of “Hold” and a consensus target price of $9.38.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Insys Therapeutics (INSY) Stock Price” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Insider Buying and Selling by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply